Audion Therapeutics is a clinical-stage company dedicated to the development of therapies to treat Hearing Loss.
Our lead program is aimed at regenerating cells and neuronal connections that are lost in patients with acquired Sensorineural Hearing Loss (SNHL), which is the most prevalent form of Hearing Loss. The program is based on scientific discoveries from the Edge lab at Massachusetts Eye and Ear Infirmary (MEEI). Initial clinical studies have shown positive results in terms of safety and efficacy of our approach.
Audion’s intellectual property and knowhow including technologies and small molecules were discovered and developed in collaboration with MEEI and Eli Lilly and are licensed by Audion. Audion’s lead product contains the gamma secretase inhibitor AUD1001 (LY3056480).
Audion recently concluded a phase I/IIa clinical study across three sites in Europe. In this study AUD1001 was shown to be safe and tolerable, and significant signs of efficacy on a variety of hearing tests were observed in multiple patients.